{"id":"W4286447573","doi":"10.1016/j.ejca.2022.06.045","title":"Impact of pharmacodynamic biomarkers in immuno-oncology phase 1 clinical trials","year":2022,"lang":"en","type":"review","venue":"European Journal of Cancer","topic":"Radiopharmaceutical Chemistry and Applications","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"Avid Radiopharmaceuticals; Astellas Pharma; CRIS Cancer Foundation; Sociedad Española de Oncología Médica; Mirati Therapeutics; Genentech; Symphogen; Bristol-Myers Squibb; AstraZeneca; Amgen; Pfizer; GlaxoSmithKline","keywords":"Biomarker; Medicine; Clinical trial; Pharmacodynamics; Oncology; Internal medicine; Imaging biomarker; Drug development; Biomarker discovery; Drug; Pharmacokinetics; Pharmacology; Radiology; Magnetic resonance imaging","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.01062738,0.0002710634,0.003419885,0.000236305,0.00002744671,0.000006967658,0.0004004707,0.00008458939,0.004789563],"category_scores_gemma":[0.001102001,0.0001841637,0.002493421,0.0004693452,0.0001608996,0.00003871331,0.00006267931,0.001507729,0.000007888475],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0006781007,"about_ca_system_score_gemma":0.002125531,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.000003674249,"about_ca_topic_score_gemma":1.413657e-7,"domain_scores_codex":[0.9913159,0.00394655,0.004008683,0.0002176502,0.0002950503,0.0002161592],"domain_scores_gemma":[0.9945642,0.001433368,0.003334787,0.000256089,0.0001040286,0.0003075179],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.001033214,0.0008334604,0.00002804542,0.001593557,0.002896411,0.0006815443,0.0000193259,0.00000575177,0.000621825,7.882265e-7,0.003473479,0.9888126],"study_design_scores_gemma":[0.006946865,0.0009748283,0.00004506297,0.002872055,0.004138343,0.0006284462,0.00001014493,0.00001630252,0.00001660163,0.000001130829,0.9842138,0.0001363804],"study_design_candidate":"design_other","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.001923773,0.9929102,0.00001691684,0.0001287646,0.0004696996,0.0004810704,0.0001606154,0.000005776848,0.0039032],"genre_scores_gemma":[0.001594573,0.9970595,0.00007495052,0.00005246016,0.0009936438,0.0000176825,0.00003167301,0.00005645673,0.0001190687],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.9886762,"threshold_uncertainty_score":0.9961202,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.4504025401027008,"score_gpt":0.6640550157850593,"score_spread":0.2136524756823586,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}